Article Details

AstraZeneca resumes asset sale in $270M COPD deal with familiar buyer Covis | FiercePharma

Retrieved on: 2021-11-02 05:04:56

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca resumes asset sale in $270M COPD deal with familiar buyer Covis | FiercePharma. View article details on hiswai:

Excerpt

AstraZeneca will sell global rights to chronic obstructive pulmonary disease inhalers Tudorza and Duaklir to Covis Pharma for $270 million, the ...

Article found on: www.fiercepharma.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up